Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies
Authors
Frank S. Zollmann
Joachim Höchel
Maximilian Feldmüller (ORCID: https://orcid.org/0000-0002-4316-2398)
Bart A. Ploeger (ORCID: https://orcid.org/0000-0003-1183-7458)
Stefan J. Jodl (ORCID: https://orcid.org/0009-0005-4268-3588)
Herbert Wiesinger (ORCID: https://orcid.org/0000-0002-3773-461X)
Andrea Wagenfeld (ORCID: https://orcid.org/0000-0001-9648-4318)
Stefan Klein (ORCID: https://orcid.org/0000-0002-3351-6551)
Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies
Frank S. Zollmann, Joachim Höchel, Maximilian Feldmüller, Bart A. Ploeger et al.
Citations
2 citations
Journal
Frontiers in Pharmacology
Topics
Immune Cell Function and Interaction
Field-Weighted Citation Impact (FWCI)
1.59
article
Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies
Frank S. Zollmann, Joachim Höchel, Maximilian Feldmüller, Bart A. Ploeger, Stefan J. Jodl, Herbert Wiesinger, Andrea Wagenfeld, Stefan Klein, Ruiping Zhang, Beate Rohde